| Biomarker ID | 105 |
| PMID | 16322291 |
| Year | 2005 |
| Biomarker | Methylation status of GSTP1 |
| Biomarker Basis | Methylation Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Patients who relapsed |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.29 (95% CI: 0.11-0.77) |
| Effect on Pathways | Pathways include: Arachidonate epoxygenase/epoxide hydrolase pathway, Multi-drug resistance factors,Glutathione conjugation,Glutathione metabolism,Prostate cancer |
| Experiment | Time to Progression |
| Type of Biomarker | Prognostic |
| Cohort | 74 patients who underwent radical prostatectomy for localised Prostate Cancer were chosen for the study. Over a period of 9 years 37 patients relapsed or died from recurrance. All the patients had a Gleason score of 7. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | P = 0.01 |
| Method Used | quantitative methylation specific PCR (QMSP) |
| Clinical | No |
| Remarks | HR for Multivariate Analysis (Considering Age, GSTP1, Cyclin D2 and APC). The major statistical end point of this study was time to progression (TTP). Progression included PSA elevations of >0.2 ng/mL, metastasis, and or death |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | GSTP1 |